Business Insider7h
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...
Targeted Oncology24d
FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer
The new target action date is January 17, 2025. The sNDA is supported by data from the phase 3 CodeBreaK 300 study presented at the 2023 ESMO Congress. At a median follow-up of 7.8 months, the median ...
Targeted Oncology26d
KEYNOTE-522 Trial: Pembrolizumab Boosts Survival in Early TNBC
Updated findings from the study were presented at the 2024 ESMO Congress and showed Results from the phase 3 KEYNOTE-522 trial (NCT03036488) in patients with early-stage triple-negative breast cancer ...
Seeking Alpha26d
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable?
Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...
The Thaiger27d
iCon Group leaves 635 investors short-changed in 232 million baht bust
The iCon Group, a beauty and supplementary products company, has become a hot topic in Thailand due to its suspicious business model, which appears to resemble a Ponzi scheme. The company reportedly ...